Gromovataya / Shutterstock.com
Does the coming into force of the Nagoya Protocol represent an overdue step in the right direction towards fairness, or more red tape and unattainable expectations? Charles Brabin, a non-practising barrister, sifts through the complexities.
Like gold panners they traverse the world, sifting through matter in the hope of striking lucky and finding immeasurable riches. Yet bioprospectors are more likely to be holding pipettes and sample tubes than metal detectors and pans. Bioprospecting involves searching for elements of the biological world that have potential commercial or scientific value.
The concept of bioprospecting and the issues it raises are not new, but rapid technological advances have brought them to the fore. In October 2014, the Nagoya Protocol of the Convention on Biological Diversity (CBD) came into force with the aim of sharing the benefits of biological wealth. However, the project is still far from completion, critics warn of its flaws and the list of ratifying countries has many gaps, including the US.
So does Nagoya represent an overdue and desperately needed step in the right direction, or more red tape and unattainable expectations?
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Nagoya Protocol; CBD